Newsletter Tool

To view this email as a web page, click here

Today's Rundown

Moderna blueprints plant upgrades to rev up vaccine supply to 3B doses a year
Seniors fully vaccinated by Pfizer, Moderna shots 94% less likely to be hospitalized for COVID-19: CDC
Just how much COVID-19 vaccine money is on the table? A whopping $157B through 2025, report says
LabCorp, still riding the COVID-19 testing wave, exceeds its own expectations with $4.2B Q1 revenue
Brii's COVID antibody combo cleared for phase 3 as it targets high-risk patients to head off hospitalization
UPDATED Coronavirus tracker: U.S. at a 'crossroads' in race between COVID-19 virus and vaccines, Fauci says
COVID-19 tracker: Lilly's arthritis drug wins quick EMA review; Teva's vaccine production offers rebuffed
CHS posts $68M loss in Q1 amid a 14% decline in admissions due to pandemic

Featured Story

Moderna blueprints plant upgrades to rev up vaccine supply to 3B doses a year

By Fraiser Kansteiner

Moderna is socking cash into its manufacturing facilities and those of its contract manufacturing partners in Europe, in a move that could lift the biotech's COVID-19 vaccine supply to a whopping 3 billion doses next year.

Seniors fully vaccinated by Pfizer, Moderna shots 94% less likely to be hospitalized for COVID-19: CDC

By Dave Muoio

The first real-world evidence of these vaccines' effectiveness among U.S. seniors promises relief to flagging providers and bolsters the case public health officials are making to hesitant Americans.

Just how much COVID-19 vaccine money is on the table? A whopping $157B through 2025, report says

By Kevin Dunleavy

In its annual projections for global drug sales, the IQVIA Institute for Human Data Science estimates that spending on COVID-19 vaccines will reach $157 billion by the end of 2025.

LabCorp, still riding the COVID-19 testing wave, exceeds its own expectations with $4.2B Q1 revenue

By Andrea Park

The vast majority of the quarter’s revenues across LabCorp's entire business were driven by organic growth, one-third of which came from COVID testing alone.

Brii's COVID antibody combo cleared for phase 3 as it targets high-risk patients to head off hospitalization

By Annalee Armstrong

Brii Biosciences has been given the green light to proceed with a phase 3 trial for a COVID-19 combination therapy in ambulatory care patients after the National Institutes of Health shut down a study of hospitalized patients in March.

UPDATED Coronavirus tracker: U.S. at a 'crossroads' in race between COVID-19 virus and vaccines, Fauci says

By Healthcare Staff

Follow along with the latest COVID-19 news straight from the Fierce Healthcare team.

COVID-19 tracker: Lilly's arthritis drug wins quick EMA review; Teva's vaccine production offers rebuffed

By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner

Europe's drug regulator said Eli Lilly's rheumatoid arthritis drug Olumiant, also known as baricitinib, would get an accelerated review for emergency use in COVID-19 patients. No company has taken up Teva's offer to help make COVID-19 vaccines, the company's CEO says. And more headlines

CHS posts $68M loss in Q1 amid a 14% decline in admissions due to pandemic

By Robert King

Community Health Systems posted a net loss of $64 million after major declines in patient admissions in the first quarter of the year.

COVID-19 Tracker